Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
07 Juni 2019 - 07:00AM
Communication from the Board of Directors
Paul Hudson to succeed Olivier
Brandicourt as Chief Executive Officer
PARIS - June 7, 2019 - At its meeting on June
6th of 2019,
Sanofi's Board of Directors unanimously appointed Paul Hudson as
Chief Executive Officer of the Group, to succeed Olivier
Brandicourt who has decided to retire.
The Board of Directors would like
to thank Olivier Brandicourt for the energy with which he has
steered the Group through a complex period and for his decisive
contribution to the company's return to growth. Thanks to the
actions undertaken during his term of office, Sanofi is able to
accelerate its growth, and has powerful assets to regain the
position it needs to occupy.
As of September 1, 2019, he will
be replaced by Paul Hudson, who most recently was Chief Executive
Officer of Novartis Pharmaceuticals and Member of the Executive
Committee of Novartis.
Paul Hudson, 51 years old, is a
seasoned leader with a strong international experience,
particularly in the United States, Japan and Europe. He spent his
28-years career with major pharmaceutical companies such as
Schering Plough, Astra Zeneca and Novartis. Throughout his various
management positions, he has proven his strategic vision, his
strong leadership and his ability to achieve the greatest
challenges, particularly in terms of innovation and digital
transformation. Mr. Hudson has a very robust track record in
successful major product launches. Paul Hudson will move to
Paris.
Serge Weinberg, Chairman of the
Board of Directors of Sanofi, said: "We are very
pleased that Paul Hudson has agreed to join Sanofi. His skills and
experience give him all the assets he needs to accelerate growth
and lead the Group's adaptation to new strategic challenges,
particularly in the areas of Research and Development and digital.
His human values will enable him to mobilize all the energies and
increase the agility, that a group such as Sanofi needs, to face
the new challenges of our industry and the changes in healthcare
systems around the world".
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
Head of Communication, Sanofi
Josep Catlla
Tél.: +33 (0) 7 89 07 80 33
Josep.catlla@sanofi.com
|
Image7
Anne Méaux
Tél.: +33 (0) 6 89 87 61 76
ameaux@image7.fr
Image7
Laurence Heilbronn
Tél.: +33 (0) 6 89 87 61 37
lheilbronn@image7.fr
|
|
About
Sanofi
Sanofi is dedicated to supporting
people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
Press Release
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Sanofi (EU:SAN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024